Table of Content

1 Report Overview
1.1 Parkinsons Disease Drug Definition
1.2 Market by Type
1.2.1 Global Parkinsons Disease Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Carbidopa/Levodopa
1.2.3 Dopamine Receptor Agonists
1.2.4 MAO-Inhibitors
1.3 Market Segment by Application
1.3.1 Global Parkinsons Disease Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Parkinsons Disease Drug Sales
2.1 Global Parkinsons Disease Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Parkinsons Disease Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Parkinsons Disease Drug Revenue by Region
2.3.1 Global Parkinsons Disease Drug Revenue by Region (2018-2024)
2.3.2 Global Parkinsons Disease Drug Revenue by Region (2024-2034)
2.4 Global Parkinsons Disease Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Parkinsons Disease Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Parkinsons Disease Drug Sales Quantity by Region
2.6.1 Global Parkinsons Disease Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Parkinsons Disease Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Parkinsons Disease Drug Sales Quantity by Manufacturers
3.1.1 Global Parkinsons Disease Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Parkinsons Disease Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Parkinsons Disease Drug Sales in 2022
3.2 Global Parkinsons Disease Drug Revenue by Manufacturers
3.2.1 Global Parkinsons Disease Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Parkinsons Disease Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Parkinsons Disease Drug Revenue in 2022
3.3 Global Parkinsons Disease Drug Sales Price by Manufacturers
3.4 Global Key Players of Parkinsons Disease Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Parkinsons Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Parkinsons Disease Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Parkinsons Disease Drug, Product Offered and Application
3.8 Global Key Manufacturers of Parkinsons Disease Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Parkinsons Disease Drug Sales Quantity by Type
4.1.1 Global Parkinsons Disease Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Parkinsons Disease Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Parkinsons Disease Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Parkinsons Disease Drug Revenue by Type
4.2.1 Global Parkinsons Disease Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Parkinsons Disease Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Parkinsons Disease Drug Revenue Market Share by Type (2018-2034)
4.3 Global Parkinsons Disease Drug Price by Type
4.3.1 Global Parkinsons Disease Drug Price by Type (2018-2024)
4.3.2 Global Parkinsons Disease Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Parkinsons Disease Drug Sales Quantity by Application
5.1.1 Global Parkinsons Disease Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Parkinsons Disease Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Parkinsons Disease Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Parkinsons Disease Drug Revenue by Application
5.2.1 Global Parkinsons Disease Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Parkinsons Disease Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Parkinsons Disease Drug Revenue Market Share by Application (2018-2034)
5.3 Global Parkinsons Disease Drug Price by Application
5.3.1 Global Parkinsons Disease Drug Price by Application (2018-2024)
5.3.2 Global Parkinsons Disease Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Parkinsons Disease Drug Sales by Company
6.1.1 North America Parkinsons Disease Drug Revenue by Company (2018-2024)
6.1.2 North America Parkinsons Disease Drug Sales Quantity by Company (2018-2024)
6.2 North America Parkinsons Disease Drug Market Size by Type
6.2.1 North America Parkinsons Disease Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Parkinsons Disease Drug Revenue by Type (2018-2034)
6.3 North America Parkinsons Disease Drug Market Size by Application
6.3.1 North America Parkinsons Disease Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Parkinsons Disease Drug Revenue by Application (2018-2034)
6.4 North America Parkinsons Disease Drug Market Size by Country
6.4.1 North America Parkinsons Disease Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Parkinsons Disease Drug Revenue by Country (2018-2034)
6.4.3 North America Parkinsons Disease Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Parkinsons Disease Drug Sales by Company
7.1.1 Europe Parkinsons Disease Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Parkinsons Disease Drug Revenue by Company (2018-2024)
7.2 Europe Parkinsons Disease Drug Market Size by Type
7.2.1 Europe Parkinsons Disease Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Parkinsons Disease Drug Revenue by Type (2018-2034)
7.3 Europe Parkinsons Disease Drug Market Size by Application
7.3.1 Europe Parkinsons Disease Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Parkinsons Disease Drug Revenue by Application (2018-2034)
7.4 Europe Parkinsons Disease Drug Market Size by Country
7.4.1 Europe Parkinsons Disease Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Parkinsons Disease Drug Revenue by Country (2018-2034)
7.4.3 Europe Parkinsons Disease Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Parkinsons Disease Drug Sales by Company
8.1.1 China Parkinsons Disease Drug Sales Quantity by Company (2018-2024)
8.1.2 China Parkinsons Disease Drug Revenue by Company (2018-2024)
8.2 China Parkinsons Disease Drug Market Size by Type
8.2.1 China Parkinsons Disease Drug Sales Quantity by Type (2018-2034)
8.2.2 China Parkinsons Disease Drug Revenue by Type (2018-2034)
8.3 China Parkinsons Disease Drug Market Size by Application
8.3.1 China Parkinsons Disease Drug Sales Quantity by Application (2018-2034)
8.3.2 China Parkinsons Disease Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Parkinsons Disease Drug Sales by Company
9.1.1 APAC Parkinsons Disease Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Parkinsons Disease Drug Revenue by Company (2018-2024)
9.2 APAC Parkinsons Disease Drug Market Size by Type
9.2.1 APAC Parkinsons Disease Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Parkinsons Disease Drug Revenue by Type (2018-2034)
9.3 APAC Parkinsons Disease Drug Market Size by Application
9.3.1 APAC Parkinsons Disease Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Parkinsons Disease Drug Revenue by Application (2018-2034)
9.4 APAC Parkinsons Disease Drug Market Size by Region
9.4.1 APAC Parkinsons Disease Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Parkinsons Disease Drug Revenue by Region (2018-2034)
9.4.3 APAC Parkinsons Disease Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Parkinsons Disease Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Parkinsons Disease Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Parkinsons Disease Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Teva
11.1.1 Teva Company Information
11.1.2 Teva Overview
11.1.3 Teva Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Teva Parkinsons Disease Drug Products and Services
11.1.5 Teva Parkinsons Disease Drug SWOT Analysis
11.1.6 Teva Recent Developments
11.2 Novartis AG
11.2.1 Novartis AG Company Information
11.2.2 Novartis AG Overview
11.2.3 Novartis AG Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Novartis AG Parkinsons Disease Drug Products and Services
11.2.5 Novartis AG Parkinsons Disease Drug SWOT Analysis
11.2.6 Novartis AG Recent Developments
11.3 GSK
11.3.1 GSK Company Information
11.3.2 GSK Overview
11.3.3 GSK Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 GSK Parkinsons Disease Drug Products and Services
11.3.5 GSK Parkinsons Disease Drug SWOT Analysis
11.3.6 GSK Recent Developments
11.4 AbbVie
11.4.1 AbbVie Company Information
11.4.2 AbbVie Overview
11.4.3 AbbVie Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 AbbVie Parkinsons Disease Drug Products and Services
11.4.5 AbbVie Parkinsons Disease Drug SWOT Analysis
11.4.6 AbbVie Recent Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Overview
11.5.3 Merck Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Merck Parkinsons Disease Drug Products and Services
11.5.5 Merck Parkinsons Disease Drug SWOT Analysis
11.5.6 Merck Recent Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Information
11.6.2 Boehringer Ingelheim Overview
11.6.3 Boehringer Ingelheim Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Boehringer Ingelheim Parkinsons Disease Drug Products and Services
11.6.5 Boehringer Ingelheim Parkinsons Disease Drug SWOT Analysis
11.6.6 Boehringer Ingelheim Recent Developments
11.7 Impax Laboratories
11.7.1 Impax Laboratories Company Information
11.7.2 Impax Laboratories Overview
11.7.3 Impax Laboratories Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Impax Laboratories Parkinsons Disease Drug Products and Services
11.7.5 Impax Laboratories Parkinsons Disease Drug SWOT Analysis
11.7.6 Impax Laboratories Recent Developments
11.8 Lundbeck
11.8.1 Lundbeck Company Information
11.8.2 Lundbeck Overview
11.8.3 Lundbeck Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Lundbeck Parkinsons Disease Drug Products and Services
11.8.5 Lundbeck Parkinsons Disease Drug SWOT Analysis
11.8.6 Lundbeck Recent Developments
11.9 Sun Pharma
11.9.1 Sun Pharma Company Information
11.9.2 Sun Pharma Overview
11.9.3 Sun Pharma Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Sun Pharma Parkinsons Disease Drug Products and Services
11.9.5 Sun Pharma Parkinsons Disease Drug SWOT Analysis
11.9.6 Sun Pharma Recent Developments
11.10 Wockhardt
11.10.1 Wockhardt Company Information
11.10.2 Wockhardt Overview
11.10.3 Wockhardt Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Wockhardt Parkinsons Disease Drug Products and Services
11.10.5 Wockhardt Parkinsons Disease Drug SWOT Analysis
11.10.6 Wockhardt Recent Developments
11.11 UCB
11.11.1 UCB Company Information
11.11.2 UCB Overview
11.11.3 UCB Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 UCB Parkinsons Disease Drug Products and Services
11.11.5 UCB Recent Developments
11.12 Bausch Health
11.12.1 Bausch Health Company Information
11.12.2 Bausch Health Overview
11.12.3 Bausch Health Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 Bausch Health Parkinsons Disease Drug Products and Services
11.12.5 Bausch Health Recent Developments
11.13 Acadia
11.13.1 Acadia Company Information
11.13.2 Acadia Overview
11.13.3 Acadia Parkinsons Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 Acadia Parkinsons Disease Drug Products and Services
11.13.5 Acadia Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Parkinsons Disease Drug Value Chain Analysis
12.2 Parkinsons Disease Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Parkinsons Disease Drug Production Mode & Process
12.4 Parkinsons Disease Drug Sales and Marketing
12.4.1 Parkinsons Disease Drug Sales Channels
12.4.2 Parkinsons Disease Drug Distributors
12.5 Parkinsons Disease Drug Customers
13 Market Dynamics
13.1 Parkinsons Disease Drug Industry Trends
13.2 Parkinsons Disease Drug Market Drivers
13.3 Parkinsons Disease Drug Market Challenges
13.4 Parkinsons Disease Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Parkinsons Disease Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Carbidopa/Levodopa
Table 3. Major Manufacturers of Dopamine Receptor Agonists
Table 4. Major Manufacturers of MAO-Inhibitors
Table 5. Global Parkinsons Disease Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Parkinsons Disease Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Parkinsons Disease Drug Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Parkinsons Disease Drug Revenue Market Share by Region (2018-2024)
Table 9. Global Parkinsons Disease Drug Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Parkinsons Disease Drug Revenue Market Share by Region (2024-2034)
Table 11. Global Parkinsons Disease Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Doses)
Table 12. Global Parkinsons Disease Drug Sales by Region (2018-2024) & (K Doses)
Table 13. Global Parkinsons Disease Drug Sales Market Share by Region (2018-2024)
Table 14. Global Parkinsons Disease Drug Sales by Region (2024-2034) & (K Doses)
Table 15. Global Parkinsons Disease Drug Sales Market Share by Region (2024-2034)
Table 16. Global Parkinsons Disease Drug Sales Quantity by Manufacturers (2018-2024) & (K Doses)
Table 17. Global Parkinsons Disease Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Parkinsons Disease Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Parkinsons Disease Drug Revenue Share by Manufacturers (2018-2024)
Table 20. Global Parkinsons Disease Drug Price by Manufacturers 2018-2024 (USD/Dose)
Table 21. Global Key Players of Parkinsons Disease Drug, Industry Ranking, 2021 VS 2022
Table 22. Global Parkinsons Disease Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Parkinsons Disease Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Parkinsons Disease Drug as of 2022)
Table 24. Global Key Manufacturers of Parkinsons Disease Drug, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Parkinsons Disease Drug, Product Offered and Application
Table 26. Global Key Manufacturers of Parkinsons Disease Drug, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Parkinsons Disease Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 29. Global Parkinsons Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 30. Global Parkinsons Disease Drug Sales Quantity Share by Type (2018-2024)
Table 31. Global Parkinsons Disease Drug Sales Quantity Share by Type (2024-2034)
Table 32. Global Parkinsons Disease Drug Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Parkinsons Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Parkinsons Disease Drug Revenue Share by Type (2018-2024)
Table 35. Global Parkinsons Disease Drug Revenue Share by Type (2024-2034)
Table 36. Parkinsons Disease Drug Price by Type (2018-2024) & (USD/Dose)
Table 37. Global Parkinsons Disease Drug Price Forecast by Type (2024-2034) & (USD/Dose)
Table 38. Global Parkinsons Disease Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 39. Global Parkinsons Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 40. Global Parkinsons Disease Drug Sales Quantity Share by Application (2018-2024)
Table 41. Global Parkinsons Disease Drug Sales Quantity Share by Application (2024-2034)
Table 42. Global Parkinsons Disease Drug Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Parkinsons Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Parkinsons Disease Drug Revenue Share by Application (2018-2024)
Table 45. Global Parkinsons Disease Drug Revenue Share by Application (2024-2034)
Table 46. Parkinsons Disease Drug Price by Application (2018-2024) & (USD/Dose)
Table 47. Global Parkinsons Disease Drug Price Forecast by Application (2024-2034) & (USD/Dose)
Table 48. North America Parkinsons Disease Drug Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Parkinsons Disease Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 50. North America Parkinsons Disease Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 51. North America Parkinsons Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 52. North America Parkinsons Disease Drug Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Parkinsons Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Parkinsons Disease Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 55. North America Parkinsons Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 56. North America Parkinsons Disease Drug Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Parkinsons Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Parkinsons Disease Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Parkinsons Disease Drug Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Parkinsons Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Parkinsons Disease Drug Sales Quantity by Country (2018-2024) & (K Doses)
Table 62. North America Parkinsons Disease Drug Sales Quantity by Country (2024-2034) & (K Doses)
Table 63. Europe Parkinsons Disease Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 64. Europe Parkinsons Disease Drug Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Parkinsons Disease Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 66. Europe Parkinsons Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 67. Europe Parkinsons Disease Drug Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Parkinsons Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Parkinsons Disease Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 70. Europe Parkinsons Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 71. Europe Parkinsons Disease Drug Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Parkinsons Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Parkinsons Disease Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Parkinsons Disease Drug Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Parkinsons Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Parkinsons Disease Drug Sales Quantity by Country (2018-2024) & (K Doses)
Table 77. Europe Parkinsons Disease Drug Sales Quantity by Country (2024-2034) & (K Doses)
Table 78. China Parkinsons Disease Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 79. China Parkinsons Disease Drug Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Parkinsons Disease Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 81. China Parkinsons Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 82. China Parkinsons Disease Drug Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Parkinsons Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Parkinsons Disease Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 85. China Parkinsons Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 86. China Parkinsons Disease Drug Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Parkinsons Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Parkinsons Disease Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 89. APAC Parkinsons Disease Drug Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Parkinsons Disease Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 91. APAC Parkinsons Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 92. APAC Parkinsons Disease Drug Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Parkinsons Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Parkinsons Disease Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 95. APAC Parkinsons Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 96. APAC Parkinsons Disease Drug Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Parkinsons Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Parkinsons Disease Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Parkinsons Disease Drug Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Parkinsons Disease Drug Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Parkinsons Disease Drug Sales Quantity by Region (2018-2024) & (K Doses)
Table 102. APAC Parkinsons Disease Drug Sales Quantity by Region (2024-2034) & (K Doses)
Table 103. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 104. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 106. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 107. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 110. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 111. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Country (2018-2024) & (K Doses)
Table 117. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity by Country (2024-2034) & (K Doses)
Table 118. Teva Company Information
Table 119. Teva Description and Overview
Table 120. Teva Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 121. Teva Parkinsons Disease Drug Product and Services
Table 122. Teva Parkinsons Disease Drug SWOT Analysis
Table 123. Teva Recent Developments
Table 124. Novartis AG Company Information
Table 125. Novartis AG Description and Overview
Table 126. Novartis AG Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 127. Novartis AG Parkinsons Disease Drug Product and Services
Table 128. Novartis AG Parkinsons Disease Drug SWOT Analysis
Table 129. Novartis AG Recent Developments
Table 130. GSK Company Information
Table 131. GSK Description and Overview
Table 132. GSK Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 133. GSK Parkinsons Disease Drug Product and Services
Table 134. GSK Parkinsons Disease Drug SWOT Analysis
Table 135. GSK Recent Developments
Table 136. AbbVie Company Information
Table 137. AbbVie Description and Overview
Table 138. AbbVie Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 139. AbbVie Parkinsons Disease Drug Product and Services
Table 140. AbbVie Parkinsons Disease Drug SWOT Analysis
Table 141. AbbVie Recent Developments
Table 142. Merck Company Information
Table 143. Merck Description and Overview
Table 144. Merck Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 145. Merck Parkinsons Disease Drug Product and Services
Table 146. Merck Parkinsons Disease Drug SWOT Analysis
Table 147. Merck Recent Developments
Table 148. Boehringer Ingelheim Company Information
Table 149. Boehringer Ingelheim Description and Overview
Table 150. Boehringer Ingelheim Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 151. Boehringer Ingelheim Parkinsons Disease Drug Product and Services
Table 152. Boehringer Ingelheim Parkinsons Disease Drug SWOT Analysis
Table 153. Boehringer Ingelheim Recent Developments
Table 154. Impax Laboratories Company Information
Table 155. Impax Laboratories Description and Overview
Table 156. Impax Laboratories Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 157. Impax Laboratories Parkinsons Disease Drug Product and Services
Table 158. Impax Laboratories Parkinsons Disease Drug SWOT Analysis
Table 159. Impax Laboratories Recent Developments
Table 160. Lundbeck Company Information
Table 161. Lundbeck Description and Overview
Table 162. Lundbeck Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 163. Lundbeck Parkinsons Disease Drug Product and Services
Table 164. Lundbeck Parkinsons Disease Drug SWOT Analysis
Table 165. Lundbeck Recent Developments
Table 166. Sun Pharma Company Information
Table 167. Sun Pharma Description and Overview
Table 168. Sun Pharma Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 169. Sun Pharma Parkinsons Disease Drug Product and Services
Table 170. Sun Pharma Parkinsons Disease Drug SWOT Analysis
Table 171. Sun Pharma Recent Developments
Table 172. Wockhardt Company Information
Table 173. Wockhardt Description and Overview
Table 174. Wockhardt Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 175. Wockhardt Parkinsons Disease Drug Product and Services
Table 176. Wockhardt Parkinsons Disease Drug SWOT Analysis
Table 177. Wockhardt Recent Developments
Table 178. UCB Company Information
Table 179. UCB Description and Overview
Table 180. UCB Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 181. UCB Parkinsons Disease Drug Product and Services
Table 182. UCB Recent Developments
Table 183. Bausch Health Company Information
Table 184. Bausch Health Description and Overview
Table 185. Bausch Health Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 186. Bausch Health Parkinsons Disease Drug Product and Services
Table 187. Bausch Health Recent Developments
Table 188. Acadia Company Information
Table 189. Acadia Description and Overview
Table 190. Acadia Parkinsons Disease Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 191. Acadia Parkinsons Disease Drug Product and Services
Table 192. Acadia Recent Developments
Table 193. Key Raw Materials Lists
Table 194. Raw Materials Key Suppliers Lists
Table 195. Parkinsons Disease Drug Distributors List
Table 196. Parkinsons Disease Drug Customers List
Table 197. Parkinsons Disease Drug Market Trends
Table 198. Parkinsons Disease Drug Market Drivers
Table 199. Parkinsons Disease Drug Market Challenges
Table 200. Parkinsons Disease Drug Market Restraints
Table 201. Research Programs/Design for This Report
Table 202. Key Data Information from Secondary Sources
Table 203. Key Data Information from Primary Sources
List of Figures
Figure 1. Parkinsons Disease Drug Product Picture
Figure 2. Global Parkinsons Disease Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Parkinsons Disease Drug Market Share by Type in 2022 & 2034
Figure 4. Carbidopa/Levodopa Product Picture
Figure 5. Dopamine Receptor Agonists Product Picture
Figure 6. MAO-Inhibitors Product Picture
Figure 7. Global Parkinsons Disease Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Parkinsons Disease Drug Market Share by Application in 2022 & 2034
Figure 9. Hospital
Figure 10. Clinics
Figure 11. Other
Figure 12. Parkinsons Disease Drug Report Years Considered
Figure 13. Global Parkinsons Disease Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Parkinsons Disease Drug Revenue 2018-2034 (US$ Million)
Figure 15. Global Parkinsons Disease Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global Parkinsons Disease Drug Sales Quantity 2018-2034 (K Doses)
Figure 17. Global Parkinsons Disease Drug Sales Quantity Market Share by Region (2018-2024)
Figure 18. Global Parkinsons Disease Drug Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America Parkinsons Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 20. North America Parkinsons Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Parkinsons Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 22. Europe Parkinsons Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Parkinsons Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 24. China Parkinsons Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC Parkinsons Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 26. APAC Parkinsons Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 28. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Parkinsons Disease Drug Sales Quantity in 2022
Figure 30. The Top 10 and Top 5 Players Market Share by Parkinsons Disease Drug Revenue in 2022
Figure 31. Parkinsons Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Parkinsons Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global Parkinsons Disease Drug Revenue Market Share by Type (2018-2034)
Figure 34. Global Parkinsons Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global Parkinsons Disease Drug Revenue Market Share by Application (2018-2034)
Figure 36. North America Parkinsons Disease Drug Revenue Market Share by Company in 2022
Figure 37. North America Parkinsons Disease Drug Sales Quantity Market Share by Company in 2022
Figure 38. North America Parkinsons Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America Parkinsons Disease Drug Revenue Market Share by Type (2018-2034)
Figure 40. North America Parkinsons Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America Parkinsons Disease Drug Revenue Market Share by Application (2018-2034)
Figure 42. North America Parkinsons Disease Drug Revenue Share by Country (2018-2034)
Figure 43. North America Parkinsons Disease Drug Sales Quantity Share by Country (2018-2034)
Figure 44. U.S. Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Parkinsons Disease Drug Sales Quantity Market Share by Company in 2022
Figure 47. Europe Parkinsons Disease Drug Revenue Market Share by Company in 2022
Figure 48. Europe Parkinsons Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe Parkinsons Disease Drug Revenue Market Share by Type (2018-2034)
Figure 50. Europe Parkinsons Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe Parkinsons Disease Drug Revenue Market Share by Application (2018-2034)
Figure 52. Europe Parkinsons Disease Drug Revenue Share by Country (2018-2034)
Figure 53. Europe Parkinsons Disease Drug Sales Quantity Share by Country (2018-2034)
Figure 54. Germany Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 55. France Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 57. Italy Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Russia Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 59. China Parkinsons Disease Drug Sales Quantity Market Share by Company in 2022
Figure 60. China Parkinsons Disease Drug Revenue Market Share by Company in 2022
Figure 61. China Parkinsons Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 62. China Parkinsons Disease Drug Revenue Market Share by Type (2018-2034)
Figure 63. China Parkinsons Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 64. China Parkinsons Disease Drug Revenue Market Share by Application (2018-2034)
Figure 65. APAC Parkinsons Disease Drug Sales Quantity Market Share by Company in 2022
Figure 66. APAC Parkinsons Disease Drug Revenue Market Share by Company in 2022
Figure 67. APAC Parkinsons Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC Parkinsons Disease Drug Revenue Market Share by Type (2018-2034)
Figure 69. APAC Parkinsons Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC Parkinsons Disease Drug Revenue Market Share by Application (2018-2034)
Figure 71. APAC Parkinsons Disease Drug Revenue Share by Region (2018-2034)
Figure 72. APAC Parkinsons Disease Drug Sales Quantity Share by Region (2018-2034)
Figure 73. Japan Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 77. India Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Parkinsons Disease Drug Sales Quantity Share by Country (2018-2034)
Figure 85. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue Share by Country (2018-2034)
Figure 86. Brazil Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 87. Mexico Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Turkey Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Israel Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 90. GCC Countries Parkinsons Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Parkinsons Disease Drug Value Chain
Figure 92. Parkinsons Disease Drug Production Process
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed